The science
Formulation & delivery platform
Retatrutide is a large peptide (molecular weight ~4,700 Da) with agonist activity at the GIP, GLP-1, and glucagon receptors. Its size and susceptibility to enzymatic degradation have historically limited it to injectable formulations. Our sublingual formulation is engineered specifically around this delivery challenge.
| Attribute | Detail |
|---|---|
| Active peptide | Retatrutide — triple agonist (GIP · GLP-1 · Glucagon) |
| Delivery platform | Self-Nanoemulsifying Drug Delivery System (SNEDDS) — spontaneously forms peptide-loaded ultra-fine droplets on contact with saliva. |
| Route | Sublingual (under the tongue) |
| Dose | 6 mg per dose (2.5 mg per metered spray, two sprays) |
| Presentation | 30 mL amber glass bottle with pump-metered sublingual sprayer |
| Excipients | Pharmaceutical-grade only — all listed in the FDA Inactive Ingredient Database. Non-irritating formulation designed for repeated sublingual use. |
| Manufacturing | GMP-standard, engineered for industrial-scale production |
| Testing | Independent third-party lab, every batch — potency, purity, contaminants |
| Storage | Room temperature. No refrigeration required. |
Why sublingual works for a peptide this size
A ~4,700 Da peptide will not survive the stomach. Even if it did, first-pass hepatic metabolism would inactivate it before it reached systemic circulation. The sublingual mucosa bypasses both barriers: it is highly vascularized, drains directly into the internal jugular vein, and does not expose the drug to digestive enzymes. What was previously an injection-only molecule becomes a two-spray at-home dose.
Placeholder — swap for the finalised technical specifications, batch certificates of analysis, and any peer-reviewed publications from the client's regulatory affairs team before launch.